Results for swp translation from Finnish to English

turvallisuustyöryhmä (swp)
safety working party (swp)

cpmp/ swp/ 668/ 02
cpmp/swp/668/02

cpmp/ swp/ 2877/ 00 rev.
cpmp/swp/2877/00 rev.

emea/ cpmp/ swp/ 1042/ 99
emea/ cpmp/ swp/1042/99

viitenumero cpmp/ swp/ 2145/ 00
cpmp/swp/2145/00

emea/ cpmp/ swp/ 2145/ 00 draft 4
emea/cpmp/swp/2145/00 draft 4

cpmp/swp/398/01 cpmp/swp/2600/01
cpmp/swp/446/00

turvallisuustyöryhmä (swp) kokoontui puheenjohtaja tri per sjöbergin johdolla kaksi kertaa vuonna 1998.
adopted in february 1998

note for guidance on photosafety testing note for guidance on specification limits for residues of metal catalysts swp conclusions and recommendations with regard to the use of genetically modified animal models for carcinogenicity assessment
swp conclusions and recommendations with regard to the use of genetically modified animal models for carcinogenicity assessment

swp osallistui yhteistyössä bwp: n kanssa dna-rokotteiden valmistukseen ja geeniterapiaan liittyvien ohjeiden laatimiseen.
released for consultation in july 1998 released for consultation in december 1998 safety working party

swp: n yhteyteen perustettiin erityistyöryhmä, joka käsitteli lääkevalmisteiden karsinogeenisuuden uusia tutkimusmenetelmiä.sen puheenjohtajana oli tri per sjöberg.
the safety working party (swp) , chaired by dr per sjöberg met twice in 1998.

asiakirjan nimi concept paper on conduct of pharmacovigilance for medicines used by children points to consider on xenogeneic cell therapy for medicinal products addendum to ich e2c ­ clinical safety data management:periodic safety update reports for marketed drugsasiakirjan nimi points to consider on the need for assessment of reproductive toxicity of human insulin analogues concept paper on the development of a cpmp position paper on the non-clinical safety studies to support low dose clinical screening studies in humans position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound note for guidance on photosafety testing note for guidance on specification limits for residues of metal catalysts swp conclusions and recommendations with regard to the use of genetically modified animal models for carcinogenicity assessment note for guidance on carcinogenic potential
cpmp/swp/5199/02points to consider on the need for assessment of reproductive toxicity of human insulin analogues concept paper on the development of a cpmp position paper on the non-clinical safety studies to support low dose clinical screening studies in humans note for guidance on photosafety testing swp conclusions and recommendations with regard to the use of genetically modified animal models for carcinogenicity assessment note for guidance on carcinogenic potential position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound note for guidance on specification limits for residues of metal catalysts note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance: